SAHPRA Approves Pfizer’s Paxlovid COVID-19 Treatment
SAHPRA announced the registration of Paxlovid COVID-19 treatment, an anti-viral medicine manufactured by Pfizer, to treat COVID-19. This is a 5-day oral treatment for mild to moderate COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.
International sources provide guidelines regarding prescribing in liver and kidney disease as well as possible drug interactions including statin therapy, anticoagulation and some hormonal birth control treatments.
Recent Posts
Novo Nordisk Announces Semaglutide Price Reduction to Improve Patient Access
Novo Nordisk Drives Semaglutide Price Reduction
Novo Nordisk slashes the US semaglutide list price—or wholesale acquisition cost (WAC)—for Wegovy®, Ozempic®, and Rybelsus® to $675 per month across key doses, effective January 1, 2027....
NICE Approves Ruxolitinib Cream for Treating Vitiligo with Facial Involvement
NICE Backs Ruxolitinib Cream Vitiligo Treatment
Ruxolitinib cream vitiligo therapy has received a major endorsement from the National Institute for Health and Care Excellence (NICE), which recommends it for non-segmental vitiligo with...
SAHPRA GMP Compliance: Addressing Allegations Against Adcock Ingram’s Clayville Facility
SAHPRA GMP compliance at Adcock Ingram's Clayville facility has been reaffirmed by the South African Health Products Regulatory Authority (SAHPRA) in its